Biodexa Pharmaceuticals (BDRX) Provisions (2016 - 2023)

Biodexa Pharmaceuticals has disclosed Provisions across 7 years of filings, most recently posting $98051.0 for Q4 2023.

• In Q4 2023, Provisions fell 59.62% year-over-year to $98051.0; the TTM figure through Dec 2023 stood at $98051.0 (down 59.62% YoY), while the FY2023 annual figure was $98262.0, down 61.64% from the prior year.
• Provisions came in at $98051.0 for Q4 2023 at Biodexa Pharmaceuticals, down from $242796.2 in the prior quarter.
• In the past five years, Provisions ranged from a high of $242796.2 in Q4 2022 to a low of $54150.5 in Q2 2022.
• Average Provisions over 5 years is $108856.0, with a median of $82725.8 recorded in 2023.
• Year-over-year, Provisions soared 260.23% in 2022 and sank 59.62% in 2023.
• Over 5 years, Provisions stood at $124715.3 in 2019, then sank by 47.06% to $66022.6 in 2020, then advanced by 2.09% to $67400.5 in 2021, then soared by 260.23% to $242796.2 in 2022, then slumped by 59.62% to $98051.0 in 2023.
• Per Business Quant data, the three most recent Provisions figures were $98051.0 in Q4 2023, $242796.2 in Q4 2022, and $54150.5 in Q2 2022.